Find Gilteritinib Fumarate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Gilteritinib hemifumarate, Asp-2215 hemifumarate, 1254053-84-3, Gilteritinib fumarate [usan], Asp2215 hemifumarate, 5rzz0z1gjt
Molecular Formula
C62H92N16O10
Molecular Weight
1221.5  g/mol
InChI Key
UJOUWHLYTQFUCU-WXXKFALUSA-N
FDA UNII
5RZZ0Z1GJT

Gilteritinib Fumarate
Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
1 2D Structure

Gilteritinib Fumarate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(E)-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
2.1.2 InChI
InChI=1S/2C29H44N8O3.C4H4O4/c2*1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36;5-3(6)1-2-4(7)8/h2*5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34);1-2H,(H,5,6)(H,7,8)/b;;2-1+
2.1.3 InChI Key
UJOUWHLYTQFUCU-WXXKFALUSA-N
2.1.4 Canonical SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=CC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=C/C(=O)O)\C(=O)O
2.2 Other Identifiers
2.2.1 UNII
5RZZ0Z1GJT
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Gilteritinib Hemifumarate

2. Asp-2215 Hemifumarate

3. 1254053-84-3

4. Gilteritinib Fumarate [usan]

5. Asp2215 Hemifumarate

6. 5rzz0z1gjt

7. 1254053-84-3 (hemifumarate)

8. 2-pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2h-pyran-4-yl)amino)-, (2e)-2-butenedioate (2:1)

9. 2-pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2h-pyran-4-yl)amino]-, (2e)-2-butenedioate (2:1)

10. 6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2h-pyran-4-yl)amino)pyrazine-2-carboxamide Hemifumarate

11. Unii-5rzz0z1gjt

12. Xospata (tn)

13. (e)-but-2-enedioic Acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide

14. Chembl3301603

15. Schembl21819929

16. Dtxsid001027950

17. Gilteritinib Fumarate (jan/usan)

18. Gilteritinib Fumarate [jan]

19. Gilteritinib Fumarate [who-dd]

20. Gilteritinib Fumarate [orange Book]

21. D10800

22. Q27262795

2.4 Create Date
2014-08-25
3 Chemical and Physical Properties
Molecular Weight 1221.5 g/mol
Molecular Formula C62H92N16O10
Hydrogen Bond Donor Count8
Hydrogen Bond Acceptor Count24
Rotatable Bond Count20
Exact Mass1220.71823320 g/mol
Monoisotopic Mass1220.71823320 g/mol
Topological Polar Surface Area317 Ų
Heavy Atom Count88
Formal Charge0
Complexity904
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Indication

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX13


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728498600,"product":"GILTERITINIB N MSN PW UD AL (3 G) B\/N- B745284","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"SANDOZ B2B","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"PIRC, KARMEN (SCIENTIST PD)","customerCountry":"SLOVENIA","quantity":"0.00","actualQuantity":"0.003","unit":"KGS","unitRateFc":"50000","totalValueFC":"148.4","currency":"USD","unitRateINR":4155146.666666667,"date":"10-Oct-2024","totalValueINR":"12465.44","totalValueInUsd":"148.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4741436","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"SANDOZ HOUSE, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728498600,"product":"GILTERITINIB N MSN PW UD AL (3 G) B\/N- B745287","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"SANDOZ B2B","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"PIRC, KARMEN (SCIENTIST PD)","customerCountry":"SLOVENIA","quantity":"0.00","actualQuantity":"0.003","unit":"KGS","unitRateFc":"50000","totalValueFC":"148.4","currency":"USD","unitRateINR":4155146.666666667,"date":"10-Oct-2024","totalValueINR":"12465.44","totalValueInUsd":"148.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4726433","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"SANDOZ HOUSE, MUMBAI ,MAHARASHTRA","customerAddress":""}]
10-Oct-2024
10-Oct-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Gilteritinib Manufacturers

A Gilteritinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gilteritinib, including repackagers and relabelers. The FDA regulates Gilteritinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gilteritinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Gilteritinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Gilteritinib Suppliers

A Gilteritinib supplier is an individual or a company that provides Gilteritinib active pharmaceutical ingredient (API) or Gilteritinib finished formulations upon request. The Gilteritinib suppliers may include Gilteritinib API manufacturers, exporters, distributors and traders.

click here to find a list of Gilteritinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Gilteritinib USDMF

A Gilteritinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Gilteritinib active pharmaceutical ingredient (API) in detail. Different forms of Gilteritinib DMFs exist exist since differing nations have different regulations, such as Gilteritinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Gilteritinib DMF submitted to regulatory agencies in the US is known as a USDMF. Gilteritinib USDMF includes data on Gilteritinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gilteritinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Gilteritinib suppliers with USDMF on PharmaCompass.

Gilteritinib WC

A Gilteritinib written confirmation (Gilteritinib WC) is an official document issued by a regulatory agency to a Gilteritinib manufacturer, verifying that the manufacturing facility of a Gilteritinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Gilteritinib APIs or Gilteritinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Gilteritinib WC (written confirmation) as part of the regulatory process.

click here to find a list of Gilteritinib suppliers with Written Confirmation (WC) on PharmaCompass.

Gilteritinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gilteritinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Gilteritinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Gilteritinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Gilteritinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gilteritinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Gilteritinib suppliers with NDC on PharmaCompass.

Gilteritinib GMP

Gilteritinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Gilteritinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gilteritinib GMP manufacturer or Gilteritinib GMP API supplier for your needs.

Gilteritinib CoA

A Gilteritinib CoA (Certificate of Analysis) is a formal document that attests to Gilteritinib's compliance with Gilteritinib specifications and serves as a tool for batch-level quality control.

Gilteritinib CoA mostly includes findings from lab analyses of a specific batch. For each Gilteritinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Gilteritinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Gilteritinib EP), Gilteritinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gilteritinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty